Angiotensin converting enzyme inhibition by captopril influences cardiac work in healthy hearts☆

Abstract

Although beneficial effects of angiotensin converting enzyme (ACE) inhibition have been demonstrated in ill (ischemic, failing) hearts, it has not been proved that ACE inhibition induces changes in healthy hearts. The question is of clinical relevance, as many hypertensive patients do not display cardiac damage at the onset of treatment with ACE inhibitors, and possible changes in cardiac work might turn out more or less advantageous in the development of hypertensive heart disease. In a refined working heart preparation allowing measurement of cardiac work, including the contribution of atrial work and paracrine cardiac regulation, effects of captopril on cardiac dynamics were assessed. Coronary overflow of bradykinin, norepinephrine, and lactate was measured. Hearts were perfused for 20 min with vehicle or captopril at 3 x 10(-8), 3 x 10(-7), 3 x 10(-6), and 3 x 10(-5) mol/L. At the highest concentration, captopril increased coronary flow. Extending previous studies, the present study demonstrates that, in a concentration-dependent manner, captopril decreased oxygen consumption and maximal left ventricular pressure although the bradykinin outflow was not affected. From these influences of the drug on cardiac work and metabolism in healthy hearts, a protective influence of captopril in acute, critical situations of cardiac malnourishment or cardiac overload may be derived.

Sinapic Acid Attenuates Cardiovascular Disorders in Rats by Modulating Reactive Oxygen Species and Angiotensin Receptor Expression

“…Bradykinin increases blood flow in the coronary arteries and inotropy and corrects endothelial functions through decreasing the metabolism of energy-rich phosphates in patients with myocardial ischemia and hypertrophy. Bradykinin stimulates the release of potent vasoactive modulators such as nitric oxide (NO), prostaglandins, and endothelium-derived hyperpolarizing factor [11].…”

Development of a new procedure for the determination of captopril in pharmaceutical formulations employing chemiluminescence and a multicommuted flow analysis approach

“…Captopril was introduced in the late 1970s as an orally active inhibitor of the angiotensin I‐converting enzyme . A survey of the scientific literature shows that research involving captopril (1‐[(2 S )‐3‐mercapto‐2‐methylpropionyl]‐l‐proline) has developed continuously over the last 40 years , indicating that this drug has become widely used for the treatment of hypertension . Because of its importance for human health, a variety of analytical procedures for its determination have been proposed, employing separation techniques such as high‐performance liquid chromatography (HPLC) and capillary electrophoresis .…”